Read More 2 minute read Funding News News Retension Pharmaceuticals Secures $10.4M Series A to Advance Phase 2 Hypertension Study Key Highlights $10.4 million Series A funding secured to advance RTN-001 for hypertension treatment. RTN-001 targets patients with uncontrolled… byChris-Anne RoqueAugust 25, 2024